Head-to-head · The Match Score
Alan Meds vs Invigor Medical
Both scored on the same six-factor Match Score. Alan Meds wins this matchup with a 86 to 85 edge — a photo finish.
Alan Meds
#7 · Grade B+
Budget shoppers who want an oral/sublingual route without giving up nationwide access.
Visit Alan MedsInvigor Medical
#10 · Grade B
Patients who want GLP-1 care alongside a wider wellness/hormone program.
Visit Invigor MedicalFactor by factor
The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.
Price, coverage & formulary
| Detail | Alan Meds | Invigor Medical |
|---|---|---|
| Semaglutide | $99/mo | $199/mo |
| Tirzepatide | $145/mo | $339/mo |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injectable only |
| Match Score | 86 · B+ | 85 · B |
Alan Meds edges out Invigor Medical, 86 to 85 on the default Match Score. Low double-digit sema pricing, an oral option, and all-50-state reach — a strong value pick for the needle-averse.
Invigor Medical is still a fair pick if its strengths line up with yours — best for: Patients who want GLP-1 care alongside a wider wellness/hormone program.
Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.
Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.
More head-to-heads
- Alan Meds vs CoreAge Rx
- Alan Meds vs Found
- Alan Meds vs Ondra Health
- Alan Meds vs Eden
- Alan Meds vs Vaylen
- Alan Meds vs Ro
Or browse alternatives to Alan Meds and all comparisons.
Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.